Perimount Magna Ease aortic valve, St. Jude Epic tissue mitral valve, prosthetic valves echo скачать в хорошем качестве

Perimount Magna Ease aortic valve, St. Jude Epic tissue mitral valve, prosthetic valves echo

In a patient who has undergone aortic valve replacement (AVR) with a Perimount Magna Ease valve and mitral valve replacement (MVR) with a St. Jude Epic tissue valve for severe aortic regurgitation (AR) and mitral regurgitation (MR), echocardiography shows normally functioning prosthetic valves. However, the patient has significant cardiac issues, including a dilated left ventricle, severely reduced ejection fraction (25%), and underlying coronary artery disease (CAD). While the prosthetic valves are functioning as expected, the overall prognosis is guarded due to the reduced ventricular function and the presence of CAD. #Prosthetic Valve Composition: The Perimount Magna Ease aortic valve is a bioprosthetic valve with bovine pericardium leaflets supported by a flexible cobalt-chromium stent. The St. Jude Epic mitral valve also uses bovine pericardium, mounted on a titanium alloy stent. Both valves are designed to be durable and resistant to calcification. #Echocardiographic Findings: *Prosthetic Aortic Valve (Perimount Magna Ease):* The valve demonstrates normal function on echocardiography. The leaflets open fully during systole, allowing unobstructed blood flow, and close completely during diastole, preventing regurgitation. Doppler imaging shows a peak velocity under 2 m/s and a mean gradient under 10 mmHg, with no significant aortic stenosis or regurgitation. Prosthetic Mitral Valve (St. Jude Epic): Echocardiography shows that the mitral valve leaflets open fully during diastole and close properly during systole. Doppler studies confirm smooth flow across the valve, with normal peak diastolic velocity and mean gradient. A trivial central jet of regurgitation is noted, but this is clinically insignificant. Overall Cardiac Function and Prognosis: Despite normal valve function, the patient has a dilated left ventricle with an ejection fraction of 25%, indicating severe systolic dysfunction. This is likely a result of chronic volume overload from the previous severe AR and MR, exacerbated by CAD. The combination of these factors places the patient at high risk for heart failure progression, arrhythmias, and sudden cardiac death. Management and Follow-Up The patient requires close monitoring and comprehensive management, including regular echocardiographic follow-up to assess valve function and left ventricular size. Heart failure management may involve diuretics, ACE inhibitors or ARBs, and beta-blockers. Aggressive management of CAD is also essential, potentially including antiplatelet therapy, statins, and lifestyle changes. The reduced ejection fraction suggests the need for consideration of an implantable cardioverter-defibrillator (ICD) to mitigate the risk of sudden cardiac death. In summary, while the prosthetic aortic and mitral valves are functioning normally, the patient’s dilated left ventricle, reduced ejection fraction, and CAD significantly impact the overall prognosis, requiring diligent long-term management. #echocardiography #heart #prostheticvalves #stjudemitralvalve #PerimountMagnaEasevalve For more visit: https://www.ultrasound-images.com/hea...